Modeling the structural basis of human CCR5 chemokine receptor function: From homology model building and molecular dynamics validation to agonist and antagonist docking

Journal of Chemical Information and Modeling

Volumn 46, Issue 3, 2006, Pages 1223-1235

  Fano, A ^a   Ritchie, D W ^b   Carrieri, A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER SIMULATION; ENZYME INHIBITION; MATHEMATICAL MODELS; MOLECULAR DYNAMICS; X RAY ANALYSIS;

CCR5 RECEPTOR; HOMOLOGY-BASED APPROACH; SYNTHETIC ANTAGONIST; THREE-DIMENSIONAL MODEL;

PROTEINS;

CHEMOKINE RECEPTOR CCR5;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; PHYSIOLOGY; PROTEIN CONFORMATION;

HUMANS; PROTEIN CONFORMATION; RECEPTORS, CCR5;

EID: 33745370466     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci050490k     Document Type: Article

References (61)

1. Cormier, E. G.; Persuh, M.; Thompson, D. A.; Lin, S. W.; Sakmar, T. P.; Olson, W. C.; Dragic, T. Specific Interaction of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines with HIV-1 Envelope Glycoprotein gp120. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5762-5777.
2. Farzan, M.; Vasilieva, N.; Schnitzler, C. E.; Chung, S.; Robinson, J.; Gerard, N. P.; Gerard, C.; Choe, H.; Sodroski, J. A Tyrosine-Sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry. J. Biol. Chem. 2000, 275, 33516-334521.
3. Cormier, E. G.: Tran, D. N.; Yukhayeva, L.; Olson W C; Dragic T. Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes. J. Virol. 2001, 75, 5541-5549.
4. Cocchi, F.; DeVico, A. L.; Garzino-Demo, A.; Arya, S. K.; Gallo, R. C.; Lusso, P. Identification of RANTES, MIP-1 Alpha, and MIP-1 Beta as the Major HIV-Suppressive Factors Produced by CD8+ T Cells. Science 1995, 270, 1811-1815.
5. Horuk, R.; Ng, H. P. Chemokine Receptor Antagonists. Med. Res. Rev. 2000, 20, 155-168.
6. Starr-Spires, L. D., Collman, R. G. HIV-1 Entry and Entry Inhibitors as Therapeutic Agents. Clin. Lab. Med. 2002, 22, 681-701.
7. Yi, Y.; Shaheen, F.; Collman, R. G. Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes. J. Virol. 2005, 79, 1480-1486.
8. Meister, S.; Otto, C.; Papkalla, A.; Krumbiegel, M.; Pohlmann, S.; Kirchhoff, F. Basic Amino Acid Residues in the V3 Loop of Simian Immunodeficiency Virus Envelope Alter Viral Coreceptor Tropism and Infectivity but Do Not Allow Efficient Utilization of CXCR4 as Entry Cofactor. Virology 2001, 284, 287-296.
9. Ditzel, H. J.; Rosenkilde, M. M.; Garred, P.; Wang, M.; Koefoed, K.; Pedersen, C.; Burton, D. R.; Schwartz, T. W. The CCR5 Receptor Acts as an Alloantigen in CCR5A32 Homozygous Individuals: Identification of Chemokines and HTV-1-Blocking Human Antibodies. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5241-5245.
10. Rojo, D.; Suetomi, K.; Navarro, J. Structural Biology of Chemokine Receptors. Biol. Res. 1999, 32, 263-272.
11. Rusconi, S.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. New Advances in HIV Entry Inhibitors Development. Curr. Drug Targets: Infect. Disord. 2004, 4, 339-355.
12. Horuk, R. Development and Evaluation of Pharmacological Agents Targeting Chemokine Receptors. Methods 2003, 29, 369-75.
13. Klabunde, T.; Hessler, G. Drug Design Strategies for Targeting G-Protein-Coupled Receptors. ChemBioChem 2002, 3, 928-944.
14. Paterlini, G. Structure Modeling of the Chemokine Receptor CCR5: Implications for Ligand Binding and Selectivity. Biophys. J. 2002, 83, 3012-3031.
15. Huang, X. Q.; Jiang, H. L.; Luo, X. M.; Chen, K. X.; Ji, R. Y.; Cao Y.; Pei, G. Building Three-Dimensional Structures of HIV-1 Coreceptor CCR5 and Its Interaction with Antagonist TAK779 by Comparative Molecular Modeling. Acta Pharmacol. Sin. 2000, 21 521-528.
16. Xu, Y.; Liu, H.; Niu, C.; Luo, C.; Luo, X.; Shen, J.; Chen, K.; Jiang H. Molecular Docking and 3D QSAR Studies on 1-Amino-2-phenyl-4-(piperidin-1-yl)- butanes Based on the Structural Modeling of Human CCR5 Receptor. Bioorg. Med. Chem. 2004, 12, 6193-6208.
17. Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F. Watson, C.; Kenakin, T. Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors Bioorg. Med. Chem. 2003, 11, 2663-2676.
18. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le, T. I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal Structure of Rhodopsin a G Protein-Coupled Receptor. Science 2000, 289, 739-745.
19. Fanelli, F.; De Benedetti, P. G. Computational Modeling Approaches to Structure-Function Analysis of G-Protein-Coupled Receptors. Chem. Rev. 2005, 105, 3297-3351.
20. Bairoch, A.; Apweiler, R. The SWISS-PROT Protein Sequence Data Bank and Its Supplement TrEMBL in 1998. Nucleic Acids Res. 1998, 26, 38-42.
21. Burkhard, R.; Casadio, R.; Fariselli, P.: Chris, S. Prediction of Helical Transmembrane Segments at 95% Accuracy. Protein Sci. 1995, 4, 521-533.
22. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence. Nucleic Acids Res. 1994, 22, 4673-4680.
23. Sali, A.; Blundell, T. L. Comparative Protein Modelling by Satisfaction of Spatial Restraints. J. Mot. Biol. 1993, 234, 779-815.
24. Blanpain, C.; Lee, B.; Vakili, J.; Doranz, B. J.; Govaerts, C.; Migeotte, I.; Sharron, M.; Dupriez, V.; Vassart, G.; Doms, R. W.; Parmentier, M. Extracellular Cysteines of CCR5 Are Required for Chemokine Binding.; but Dispensable for HIV-1 Coreceptor Activity. J. Biol. Chem. 1999, 274, 18902-18908.
25. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A Program To Check the Stereochemical Quality of Protein Structures. J. Appl. Crystallogr. 1993, 26, 283-291.
26. Carrieri, A.; Centeno, N. B.; Rodrigo, J.; Sanz, F.; Carotti, A. Theoretical Evidence of a Salt Bridge Disruption as the Initiating Process for the Alpha1d-adrenergic Receptor Activation: A Molecular Dynamics and Docking Study. Proteins: Struct., Funct., Genet. 2001, 43, 382-394.
27. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S., Jr.; Weiner, P. A New Force Field for Molecular Mechanical Simulation of Nucleic Acids and Proteins. J. Am. Chem. Soc. 1984, 106, 765-784.
28. Rohrig, U. F.; Guidoni, L.; Rothlisberger, U. Early Steps of the Intramolecular Signal Transduction in Rhodopsin Explored by Molecular Dynamics Simulations. Biochemistry 2002, 41, 10799-809.
29. Rohrig, U. F.; Guidoni, L.; Rothlisberger, U. Solvent and Protein Effects on the Structure and Dynamics of the Rhodopsin Chromophore. ChemPhysChem 2005, 6, 1836-1847.
30. Lazaridis, T. Implicit Solvent Simulations of Peptide Interactions with Anionic Lipidmembranes. Proteins 2005, 58, 518-27.
31. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical Integration of the Cartesian Equation of Motion of a System Constraints: Molecular Dynamics of N-Alkanes. J. Comput. Phys. 1977, 23, 327-341.
32. Kelley, L.; Gardner, S.; Sutcliffe, M. An Automated Approach for Clustering an Ensemble of NMR-Derived Protein Structures into Conformationally-Related Subfamilies. Protein Eng. 1996, 9, 1063-1065.
33. Frishman, D.; Argos P. Knowledge-Based Protein Secondary Structure Assignment. Proteins: Struct., Funct., Genet. 1995, 23, 556-579.
34. Gentili, F.; Ghelfi, F.; Giannella, M.; Piergentili, A.; Pigini, M.; Quaglia, W.; Vesprini, C.; Crassous, P. A.; Paris, H.; Carrieri, A. α2-Adrenoreceptors Profile Modulation. 2. Biphenyline Analogues as Tools for Selective Activation of the α2C-Subtype. J. Med. Chem. 2004, 47, 6160-73.
35. McMartin, C.; Bohacek, R. S. QXP: Powerful Rapid Computer Algorithms for Structure-Based Drug Design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.
36. Dragic, T.; Trkola, A.; Thompson, D. A.; Cormier, E. G.; Kajumo, F. A.; Maxwell, E.; Lin, S. W.; Ying, W.; Smith, S. O.; Sakmar, T. P.; Moore, J. P. A Binding Pocket for a Small Molecule Inhibitor of HIV-1 Entry within the Transmembrane Helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5639-5644.
37. Ritchie, D. W.; Kemp, G. J. L. Protein Docking Using Spherical Polar Fourier Correlations. Proteins: Struct., Funct., Genet. 2000, 39, 178-194.
38. Fano, A. Using Molecular Interaction Fields to Improve the Scoring of Protein-Protein Interactions: Application to CCR5-Chemokines System and HTV-Blockers, from Pharmacophore, to Theoretical Model, to Docking. Ph.D. Thesis, Faculty of Pharmacy, University of Bari. Bari, Italy, 2004.
39. Goodford, P. J. A Computational Procedure for Determining Energetically Favourable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
40. Janin, J. Assessing Predictions of Protein-Protein Interaction: The CAPRI Experiment. Protein Sci. 2005, 14, 278-283.
41. Mendez, R.; Leplae, R.; Lensink, M. F.; Wodak, S. J. Assessment of CAPRI Predictions in Rounds 3-5 Shows Progress in Docking Procedures. Proteins: Struct., Funct., Bioinf. 2005, 60, 150-169.
42. Sussman, J. L.; Lin, D.; Jiang, J.; Manning, N. O.; Prilusky, J.; Ritter. O.; Abola, E. E. Protein Data Bank (PDB): Database of Three-Dimensional Structural Information of Biological Macromolecules. Acta Cryst. 1998, 54, 1078-1084.
43. Skelton, N. J.; Aspiras, F.; Ogez, J.; Schall, T. J. Proton NMR Assignments and Solution Conformation of RANTES, a Chemokine of the C-C Type. Biochemistry 1995, 34, 5329-5342.
44. Lodi, P. J.; Garrett, D. S.; Kuszewski, J.; Tsang, M. L.; Weatherbee, J. A.; Leonard, W. J.; Gronenborn, A. M.; Clore, G. M. High-Resolution Solution Structure of the Beta Chemokine hMIP-1 Beta by Multidimensional NMR. Science 1994, 263, 1762-1767.
45. GOLPE, version 4.5; Multivariate Informatic Analysis Sri: Perugia, Italy, 1999.
46. Nardese, V.; Longhi, R.; Polo, S.; Sironi, F.; Arcelloni, C.; Paroni, R.; DeSantis, C.; Sarmientos, P.; Rizzi, M.; Bolognesi, M.; Pavone, V.; Lusso, P. Structural Determinants of CCR5 Recognition and HIV-1 Blockade in RANTES. Nat. Struct. Biol. 2001, 8, 611-615.
47. Chabot, D. J.; Broder, C. C. Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry. J. Biol. Chem. 2000, 275, 23774-23782.
48. 1B-Adrenergic Receptor: Role of Highly Conserved Polar Amino Acids in Receptor Activation. EMBO J. 1996, 15, 3566-3578.
49. Govaerts, C.; Blanpain, C.; Deupi, X.; Ballet, S.; Ballesteros, J. A.; Wodak, S. J.; Vassart, G.; Pardo, L.; Parmentier, M. The TXP Motif in the Second Transmembrane Helix of CCR5. A Structural Determinant of Chemokine-Induced Activation. J. Biol. Chem. 2001, 276, 13217-13225.
50. Govaerts, C.; Bondue, A.; Springael, J. Y.; Olivella, M.; Deupi, X.; Le Poul, E.; Wodak, S. J.; Parmentier, M.; Pardo, L.; Blanpain, C. Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3. J. Biol. Chem. 2003, 278, 1892-1903.
51. Blanpain, C.; Doranz, B. J.; Vakili, J.; Rucker, J.; Govaerts, C.; Baik, S. S.; Lorthioir, O.; Migeotte, I.; Libert, F.; Baleux, F.; Vassart, G.; Doms, R. W.; Parmentier, M. Multiple Charged and Aromatic Residues in CCR5 Amino-Terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein. J. Biol. Chem. 1999, 274, 34719-34727.
52. Dragic, T.; Trkola, A.; Lin, S. W.; Nagashima, K. A.; Kajumo, F.; Zhao, L.; Olson, W. C.; Wu, L.; Mackay, C. R.; Allaway, G. P.; Sakmar, T. P.; Moore, J. P.; Maddon, P. J. Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry. J. Virol. 1998, 72, 279-285.
53. Farzan, M.; Choe, H.; Vaca, L.; Martin, K.; Sun, Y.; Desjardins, E.; Ruffing, N.; Wu, L.; Wyatt, R.; Gerard, N.; Gerard, C.; Sodroski, J. A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association Between gp120 and CCR5. J. Virol. 1998, 72, 1160-1164.
54. Genoud, S.; Kajumo, F.; Guo, Y.; Thompson, D.; Dragic, T. CCR5-Mediated Human Immunodeficiency Virus Entry Depends on an Amino-Terminal gp120-Binding Site and on the Conformational Integrity of All Four Extracellular Domains. J. Virol. 1999, 73, 1645-1648.
55. Rabut, G. E.; Konner, J. A.; Kajumo, F.; Moore, J. P.; Dragic, T. Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage-and Dualtropic Isolates of Human Immunodeficiency Virus Type 1. J. Virol. 1998, 72, 3464-3468.
56. Navenot, J. M.; Wang, Z. X.; Trent, J. O.; Murray, J. L.; Hu, Q. X.; DeLeeuw, L.; Moore, P. S.; Chang, Y.: Peiper, S. C. Molecular Anatomy of CCR5 Engagement by Physiologic and Viral Chemokines and HIV-1 Envelope Glycoproteins: Differences in Primary Structural Requirements for RANTES.; MIP-1 Alpha.; and vMIP-II Binding. J. Mol. Biol. 2001, 313, 1181-1193.
57. Blanpain, C.; Doranz, B. J.; Bondue, A.; Govaerts, C.; De Leener, A.; Vassart, G.; Doms, R. W.; Proudfoot, A.; Parmentier, M. The CoreDomain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle. J. Biol. Chem. 2003, 278, 5179-5187.
58. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K.; Fujino, M. A Small-Molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective anti-HTV-1 Activity. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5698-5703.
59. Olson, W. C.; Rabut, G. E.; Nagashima, K. A.; Tran, D. N.; Anselma, D. J.; Monard, S. P.; Segal, J. P.; Thompson, D. A.; Kajumo, F.; Guo, Y.; Moore, J. P.; Maddon, P. J.; Dragic, T. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp 120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5. J. Virol. 1999, 73, 4145-4155.
60. Ross, T. M.; Bieniasz, P. D.; Cullen, B. R. Multiple Residues Contribute to the Inability of Murine CCR-5 To Function as a Coreceptor for Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates. J. Virol. 1998, 72, 1918-1924.
61. Hubbard, S. J.; Thornton, J. M. "NACESS", Computer Program; Department of Biochemistry and Molecular Biology: University College of London, 1993.